LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Pulse Biosciences Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

25.45 7.66

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

23.53

Max

25.62

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-217K

-19M

Pardavimai

86K

86K

Pelnas, tenkantis vienai akcijai

-0.29

Pelno marža

-22,540.698

Darbuotojai

75

EBITDA

-228K

-19M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+30.38% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-179M

958M

Ankstesnė atidarymo kaina

17.79

Ankstesnė uždarymo kaina

25.45

Naujienos nuotaikos

By Acuity

45%

55%

154 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Pulse Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-17 23:44; UTC

Karštos akcijos

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

2026-02-17 23:20; UTC

Uždarbis

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

2026-02-17 22:57; UTC

Uždarbis

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

2026-02-17 21:59; UTC

Uždarbis

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

2026-02-17 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

2026-02-17 23:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-17 23:54; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-17 23:45; UTC

Rinkos pokalbiai

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

2026-02-17 23:19; UTC

Uždarbis

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

2026-02-17 23:15; UTC

Uždarbis

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

2026-02-17 22:58; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

2026-02-17 22:58; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

2026-02-17 22:57; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

2026-02-17 22:50; UTC

Įsigijimai, susijungimai, perėmimai

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

2026-02-17 22:44; UTC

Uždarbis

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

2026-02-17 22:42; UTC

Uždarbis

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

2026-02-17 22:36; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

2026-02-17 22:36; UTC

Uždarbis

Santos Final Dividend 10.3 U.S. Cents/Security

2026-02-17 22:36; UTC

Uždarbis

Santos FY Underlying Profit US$898 Million, Down 25%

2026-02-17 22:35; UTC

Uždarbis

Santos FY Revenue US$4.94 Billion, Down 8%

2026-02-17 22:35; UTC

Uždarbis

Correct: Santos FY Net Profit US$818 Million, Down 33%

2026-02-17 22:35; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

2026-02-17 22:34; UTC

Uždarbis

Santos FY Net Profit US$818 Billion, Down 33%

2026-02-17 22:02; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

2026-02-17 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

2026-02-17 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-02-17 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-17 21:49; UTC

Įsigijimai, susijungimai, perėmimai

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

2026-02-17 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

2026-02-17 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Akcijų palyginimas

Kainos pokytis

Pulse Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

30.38% į viršų

12 mėnesių prognozė

Vidutinis 30 USD  30.38%

Aukščiausias 30 USD

Žemiausias 30 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pulse Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

16.59 / 17.17Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

154 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
help-icon Live chat